keyword
MENU ▼
Read by QxMD icon Read
search

randomized, double-blind, trial

keyword
https://www.readbyqxmd.com/read/29334721/efficacy-and-safety-of-tocilizumab-in-korean-patients-with-active-rheumatoid-arthritis
#1
Han Joo Baek, Mie Jin Lim, Won Park, Sung Hwan Park, Seung-Cheol Shim, Dae-Hyun Yoo, Hyun Ah Kim, Soo Kon Lee, Yun Jong Lee, Young Eun Park, Hoon-Suk Cha, Yeong-Wook Song
Background/Aims: To investigate the efficacy and safety of tocilizumab (TCZ) humanized anti-interleukin-6 receptor monoclonal antibody, in Korean patients with active rheumatoid arthritis (RA) refractory to conventional disease modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX). Methods: The main study was a 24-week, randomized, double-blind, controlled trial that was followed by a 48-week, open-labeled, extension phase. TCZ (8 mg/kg) or placebo was intravenously administered every 4 weeks...
January 17, 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29334636/impact-of-demographic-factors-on-the-antidepressant-effect-a-patient-level-data-analysis-from-depression-trials-submitted-to-the-pharmaceuticals-and-medical-devices-agency-in-japan
#2
Tetsuo Nakabayashi, Ayako Hara, Hirofumi Minami
A substantial and variable placebo response can cause unreliable findings in clinical trials designed to demonstrate the efficacy of antidepressants, and the high rate of failed trials represents a major obstacle in the development of new drugs for major depressive disorder (MDD). However, the influence of demographic and symptom factors on the antidepressant effect remains to be established. The purpose of this study was to estimate the magnitude of this influence. A patient-level meta-analysis of data from double-blind, randomized, placebo-controlled trials involving the use of antidepressants for adults with MDD was performed...
January 3, 2018: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/29334438/in-vitro-and-in-vivo-evaluations-of-the-anticalculus-effect-of-a-novel-stabilized-stannous-fluoride-dentifrice
#3
Tao He, Mary Kay Anastasia, Marianne Zsiska, Teresa Farmer, Eva Schneiderman, Jeffery L Milleman
OBJECTIVES: To evaluate the effect of a novel stannous fluoride dentifrice with zinc citrate on calculus inhibition using both in vitro and clinical models. METHODS: Each investigation tested a novel stabilized 0.454% stannous fluoride dentifrice with zinc citrate as an anticalculus agent (Crest® Pro-Health™ smooth formula) compared to a negative control fluoride dentifrice. The in vitro study used the modified Plaque Growth and Mineralization Model (mPGM). Plaque biofilms were prepared and mineralized by alternate immersion of glass rods in human saliva and artificial mineralization solution...
December 2017: Journal of Clinical Dentistry
https://www.readbyqxmd.com/read/29334437/a-randomized-clinical-trial-to-measure-the-erosion-protection-benefits-of-a-novel-stabilized-stannous-fluoride-dentifrice-versus-a-control-dentifrice
#4
Xinyi Zhao, Tao He, Yanyan He, Cathy Cheng, Haijing Chen
OBJECTIVES: The aim of this investigation was to assess the erosion protection ability of a novel stabilized stannous fluoride (SnF2) dentifrice and a control sodium fluoride dentifrice (NaF) using a well-credentialed human in situ model. METHODS: A novel smooth texture 0.454% stabilized SnF2 dentifrice (Crest® Pro-Health™ smooth formula) and a 0.23% NaF marketed control dentifrice with 5% potassium nitrate (Sensodyne® Pronamel®) were compared in a 10-day, single center, randomized, controlled, double-blind, two-treatment, three-period crossover in situ clinical trial...
December 2017: Journal of Clinical Dentistry
https://www.readbyqxmd.com/read/29334436/assessment-of-the-effects-of-a-novel-stabilized-stannous-fluoride-dentifrice-on-gingivitis-in-a-two-month-positive-controlled-clinical-study
#5
Tao He, Rachelle Eusebio, C R Goyal, Jimmy G Qaqish
OBJECTIVES: The aim of this study was to compare the antibleeding/antigingivitis effectiveness of a newly formulated 0.454% stabilized stannous fluoride dentifrice and a marketed positive control triclosan-containing dentifrice in adults with mild-to-moderate gingivitis. METHODS: This single-center, two-month, randomized and controlled, double-blind, parallel group clinical trial involved adults with preexisting mild-to-moderate gingivitis. Baseline bleeding and gingivitis levels were assessed with the Gingival Bleeding Index (GBI) and Lobene Modified Gingival Index (MGI)...
December 2017: Journal of Clinical Dentistry
https://www.readbyqxmd.com/read/29334435/comparative-antiplaque-effect-of-two-antimicrobial-dentifrices-laboratory-and-clinical-evaluations
#6
Lynn R Friesen, C R Goyal, Jimmy G Qaqish, Tao He, Rachelle Eusebio, Marianne Zsiska, Teresa Farmer, Eva Schneiderman
OBJECTIVES: To compare the effect of a stannous fluoride dentifrice versus a triclosan-containing dentifrice on the reduction of plaque using in vitro and clinical models. METHODS: Both investigations evaluated a novel 0.454% stabilized stannous fluoride dentifrice (Crest® Pro-Health™ smooth formula) versus a sodium fluoride/triclosan positive control dentifrice (Colgate® Total®). The in vitro evaluation utilized the Plaque Glycolysis and Regrowth Model (PGRM), wherein the metabolic effects (acid production/glycolysis inhibition) of the dentifrices were assessed on plaque biofilms grown on glass rods after three days growth and a single dentifrice treatment...
December 2017: Journal of Clinical Dentistry
https://www.readbyqxmd.com/read/29334040/botulinum-toxin-type-a-for-pain-in-advanced-parkinson-s-disease
#7
Veronica Bruno, Maria Eliza Freitas, Deborah Mancini, Jane P Lui, Janis Miyasaki, Susan H Fox
Background and Objective Pain is a frequent symptom in Parkinson's disease (PD), and the therapeutic alternatives are scarce. The goal of this trial was to measure the effects of botulinum toxin type A (BTXA) in the treatment of limb pain in advanced PD. Methods A randomized double-blind crossover versus placebo study of BTXA for limb pain in advanced Parkinson's disease was conducted. Subjects received individualized BTXA/placebo dosing per pain distribution in limbs. The primary outcome was a measure of change in global pain on a numeric rating scale (NRS) at 4 and 12 weeks postinjection and on a visual analogue scale 12 weeks after treatment...
January 2018: Canadian Journal of Neurological Sciences. le Journal Canadien des Sciences Neurologiques
https://www.readbyqxmd.com/read/29333721/carbohydrate-dose-influences-liver-and-muscle-glycogen-oxidation-and-performance-during-prolonged-exercise
#8
Andy J King, John P O'Hara, Douglas J Morrison, Tom Preston, Roderick F G J King
This study investigated the effect of carbohydrate (CHO) dose and composition on fuel selection during exercise, specifically exogenous and endogenous (liver and muscle) CHO oxidation. Ten trained males cycled in a double-blind randomized order on 5 occasions at 77% V˙O2max for 2 h, followed by a 30-min time-trial (TT) while ingesting either 60 g·h-1 (LG) or 75 g·h-113 C-glucose (HG), 90 g·h-1 (LGF) or 112.5 g·h-113 C-glucose-13 C-fructose ([2:1] HGF) or placebo. CHO doses met or exceed reported intestinal transporter saturation for glucose and fructose...
January 2018: Physiological Reports
https://www.readbyqxmd.com/read/29332708/management-of-psoriasis-in-patients-with-inflammatory-bowel-disease-from-the-medical-board-of-the-national-psoriasis-foundation
#9
REVIEW
Scott M Whitlock, Clinton W Enos, April W Armstrong, Alice Gottlieb, Richard G Langley, Mark Lebwohl, Joseph F Merola, Caitriona Ryan, Michael P Siegel, Jeffrey M Weinberg, Jashin J Wu, Abby S Van Voorhees
BACKGROUND: There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD. OBJECTIVE: To assess therapeutic options for patients with psoriasis and concurrent IBD. METHODS: A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017...
February 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29332430/effect-of-creatine-phosphate-sodium-on-bispectral-index-and-recovery-quality-during-the-general-anaesthesia-emergence-period-in-elderly-patients-a-randomized-double-blind-placebo-controlled-trial
#10
Wei Wang, Wan-You Yu, Jie Lv, Lian-Hua Chen, Zhong Li
Objective To evaluate the effect of creatine phosphate sodium on bispectral index (BIS) and recovery quality during the general anaesthesia emergence period in elderly patients. Methods This randomized, double-blind, placebo-controlled study enrolled patients undergoing transabdominal cholecystectomy under general anaesthesia. Patients were randomly assigned to receive either creatine phosphate sodium (1.0 g/100 ml 0.9% saline; group P) or 100 ml 0.9% saline (group C) over 30 minutes during surgical incision...
January 1, 2018: Journal of International Medical Research
https://www.readbyqxmd.com/read/29332222/efficacy-of-crocus-sativus-saffron-in-treatment-of-major-depressive-disorder-associated-with-post-menopausal-hot-flashes-a-double-blind-randomized-placebo-controlled-trial
#11
Ladan Kashani, Sophia Esalatmanesh, Farzaneh Eftekhari, Samrand Salimi, Tahereh Foroughifar, Farnaz Etesam, Hamideh Safiaghdam, Ehsan Moazen-Zadeh, Shahin Akhondzadeh
PURPOSE: Due to concerns regarding the side effects of hormone therapy, many studies have focused on the development of non-hormonal agents for treatment of hot flashes. The aim of this study was to evaluate the efficacy and safety of saffron (stigma of Crocus sativus) in treatment of major depressive disorder associated with post-menopausal hot flashes. METHODS: Sixty women with post-menopausal hot flashes participated in this study. The patients randomly received either saffron (30 mg/day, 15 mg twice per day) or placebo for 6 weeks...
January 13, 2018: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/29332050/supplemental-retinal-carotenoids-enhance-memory-in-healthy-individuals-with-low-levels-of-macular-pigment-in-a-randomized-double-blind-placebo-controlled-clinical-trial
#12
Rebecca Power, Robert F Coen, Stephen Beatty, Riona Mulcahy, Rachel Moran, Jim Stack, Alan N Howard, John M Nolan
BACKGROUND: There is a biologically plausible rationale whereby the dietary carotenoids lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ), which are collectively referred to as macular pigment (MP) in the central retina (macula), support the maintenance of cognition via their antioxidant and anti-inflammatory properties. OBJECTIVE: To investigate the impact of supplemental L, Z, and MZ on memory, executive function, and verbal fluency among healthy individuals with low MP levels...
2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29331959/probenecid-improves-cardiac-function-in-patients-with-heart-failure-with-reduced-ejection-fraction-in-vivo-and-cardiomyocyte-calcium-sensitivity-in-vitro
#13
Nathan Robbins, Mark Gilbert, Mohit Kumar, James W McNamara, Patrick Daly, Sheryl E Koch, Ginger Conway, Mohamed Effat, Jessica G Woo, Sakthivel Sadayappan, Jack Rubinstein
BACKGROUND: Transient receptor potential vanilloid 2 is a calcium channel activated by probenecid. Probenecid is a Food and Drug Administration-approved uricosuric drug that has recently been shown to induce positive lusitropic and inotropic effects in animal models through cardiomyocyte transient receptor potential vanilloid 2 activation. The aim of this study was to test the hypothesis that oral probenecid can improve cardiac function and symptomatology in patients with heart failure with reduced ejection fraction and to further elucidate its calcium-dependent effects on myocyte contractility...
January 13, 2018: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29331722/effect-of-vitamin-d-supplementation-on-serum-sclerostin-levels-in-chronic-kidney-disease
#14
REVIEW
Ashok Kumar Yadav, Vivek Kumar, Debasish Banerjee, Krishan Lal Gupta, Vivekanand Jha
Vitamin D deficiency, cardiovascular disease and abnormal bone mineral metabolism are common in chronic kidney disease (CKD). Abnormal bone mineral metabolism has been linked to vascular calcification in CKD. Sclerostin has emerged as an important messenger in cross talk between bone-vascular axis. We analyzed sclerostin in subjects who participated in the randomized, double blind, placebo controlled trial investigating the effect of cholecalciferol supplementation on vascular function in non-diabetic CKD stage G3-4 and vitamin D ≤20ng/ml [CTRI/2013/05/003648]...
January 10, 2018: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/29331711/omega-3-supplements-reduce-self-reported-physical-aggression-in-healthy-adults
#15
Laurent Bègue, Ap Zaalberg, Rébecca Shankland, Aaron Duke, Julie Jacquet, Perla Kaliman, Lucie Pennel, Marc Chanove, Philippe Arvers, Brad J Bushman
There is emerging evidence that Omega-3 polyunsaturated fatty acids (PUFA) supplements can decrease aggression. However, experimental studies with adults from non-specific populations are scarce. We hypothesized that Omega-3 supplements would decrease self-reported aggression among non-clinical participants. In a double-blind randomized trial, two groups of participants (N = 194) aged 18-45 from the general population followed a 6-weeks treatment with 638mg docosahexaenoic acid (DHA) and 772mg eicosapentaenoic acid (EPA) per day or the equivalent quantity of copra oil (placebo)...
December 15, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/29331701/the-use-of-triiodothyronine-t3-in-the-treatment-of-bipolar-depression-a-review-of-the-literature
#16
REVIEW
T Parmentier, P Sienaert
BACKGROUND: There is a paucity of treatment options for bipolar depression. The use of triiodothyronine (T3) has been suggested as adjunctive treatment. METHODS: A search on Medline, Limo and ScienceDirect was performed using the search terms bipolar disorder, bipolar depression, treatment resistant, treatment refractory, thyroid hormones, triiodothyronine, T3, acceleration and augmentation. RESULTS: We retrieved three open studies, one comparative study, two double blind and one retrospective chart review...
January 9, 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29330660/theobromine-consumption-does-not-improve-fasting-and-postprandial-vascular-function-in-overweight-and-obese-subjects
#17
Lotte Smolders, Ronald P Mensink, Jose J van den Driessche, Peter J Joris, Jogchum Plat
BACKGOUND: Theobromine, a component of cocoa, may favorably affect conventional lipid-related cardiovascular risk markers, but effects on flow-mediated dilation (FMD) and other vascular function markers are not known. OBJECTIVE: To evaluate the effects of 4-week theobromine consumption (500 mg/day) on fasting and postprandial vascular function markers. DESIGN: In a randomized, double-blind crossover study, 44 apparently healthy overweight (N = 30) and obese (N = 14) men and women with low HDL-C concentrations, consumed daily 500 mg theobromine or placebo for 4 weeks...
January 12, 2018: European Journal of Nutrition
https://www.readbyqxmd.com/read/29330620/impact-of-sirtuin-1-expression-on-h3k56-acetylation-and-oxidative-stress-a-double-blind-randomized-controlled-trial-with-resveratrol-supplementation
#18
Simona Bo, Gabriele Togliatto, Roberto Gambino, Valentina Ponzo, Giusy Lombardo, Rosalba Rosato, Maurizio Cassader, Maria Felice Brizzi
AIMS: Sirtuin-1 (SIRT-1) down-regulation in type 2 diabetes mellitus (T2DM) has been associated with epigenetic markers of oxidative stress. We herein aim to evaluate whether an increase in SIRT-1 expression affects histone 3 acetylation at the 56 lysine residue (H3K56ac) in T2DM patients randomly selected to receive either resveratrol (40 mg or 500 mg) or a placebo for 6 months. The primary outcome is changes in the H3K56ac level by variation in SIRT-1 expression and the secondary outcome is the evidence of association between SIRT-1 level, antioxidant markers (TAS), and metabolic variables...
January 12, 2018: Acta Diabetologica
https://www.readbyqxmd.com/read/29330573/tocotrienol-supplementation-suppressed-bone-resorption-and-oxidative-stress-in-postmenopausal-osteopenic-women-a-12-week-randomized-double-blinded-placebo-controlled-trial
#19
C-L Shen, S Yang, M D Tomison, A W Romero, C K Felton, H Mo
Tocotrienols have shown bone-protective effect in animals. This study showed that a 12-week tocotrienol supplementation decreased concentrations of bone resorption biomarker and bone remodeling regulators via suppressing oxidative stress in postmenopausal osteopenic women. INTRODUCTION: Tocotrienols (TT) have been shown to benefit bone health in ovariectomized animals, a model of postmenopausal women. The purpose of this study was to evaluate the effect of 12-week TT supplementation on bone markers (serum bone-specific alkaline phosphatase (BALP), urine N-terminal telopeptide (NTX), serum soluble receptor activator of nuclear factor-kappaB ligand (sRANKL), and serum osteoprotegerin (OPG)), urine calcium, and an oxidative stress biomarker (8-hydroxy-2'-deoxyguanosine (8-OHdG)) in postmenopausal women with osteopenia...
January 12, 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29330194/telotristat-ethyl-in-carcinoid-syndrome-safety-and-efficacy-in-the-telecast-phase-3-trial
#20
Marianne E Pavel, David J Gross, Marta Benavent, Petros Perros, Raj Srirajaskanthan, Richard R P Warner, Matthew H Kulke, Lowell Anthony, Pamela Kunz, Dieter Hörsch, Martin O Weickert, Pablo Lapuerta, Wenjun Jiang, Kenneth Kassler-Taub, Suman Wason, Rosanna Fleming, Douglas Fleming, Rocio García-Carbonero
Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the Phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs (SSAs). TELECAST, a Phase 3 companion study, assessed safety and efficacy of telotristat ethyl in patients with CS (diarrhea, flushing, abdominal pain, nausea, or elevated urinary 5-hydroxyindoleacetic acid [u5-HIAA]) with <4 BMs/day on SSAs (or ≥1 symptom or ≥4 BMs/day if not on SSAs) during a 12-week double-blind treatment period followed by a 36-week open-label extension (OLE)...
January 12, 2018: Endocrine-related Cancer
keyword
keyword
63876
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"